The share of children aged 8 to 11 years with obesity who were prescribed glucagon-like peptide-1 (GLP-1) receptor agonists rose 310-fold between January 2019 and June 2026, even though absolute use ...

Francesca Puggioni, MD, discusses real-world exacerbations, biomarker-driven access, and barriers to earlier biologic use in asthma and COPD. Panel discussions and abstract presentations at the ...

Ifosfamide shortages affect 94% of centers, with notable constraints also reported for carboplatin, cisplatin, BCG, and ...

A higher weight-adjusted waist index (WWI) was independently linked to greater all-cause and CVD mortality in CKD, partly via ...

Economic modeling suggested meaningful savings via reduced disability costs and avoidance of inpatient admissions for compounded ophthalmic therapy, with projected annual patient savings of roughly ...

In "Inside the Be Well Trials: Design, Population, and Patient Selection," the panel walks through why the Be Well trials ...

In "Counseling Vitiligo Patients on Time to Repigmentation," Dr. Desai and Dr. Lal discuss how to counsel patients through ...

In "Cross-Trial Vitiligo Data: What Payers Can and Can't Compare," the panel compares cross-trial data directly and discusses ...

This episode, "How Bepirovirsen Targets the Hepatitis B Viral Lifecycle," features the panel debating how much of this ...

From a health system perspective, Martyn suggested that broader formulary access to finerenone makes sense as long as patient ...

AJMC: Your study found that emphysema affecting at least 20% of the lung on CT was consistently associated with differences ...